AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05834478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Cervical Vagal Nerve Stimulation
Description: Participants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain \[typically 10-30 V and 60milliamperes (mA) (peak)\], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).
Study NCT05834478 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Participants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.
Study NCT05834478 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: [F-18]Fallypride
Description: \[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
Study NCT05834478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]Fallypride
Description: \[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
Study NCT05483465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Oral NR, 1g/day per os for 8 weeks
Study NCT05483465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical pill to NR, daily per os for 8 weeks
Study NCT05943184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Nursing Model
Description: (1)Psychological intervention was accessible to those who felt resistant to their treatment plans or developed inferior feelings due to visual impairment to establish a good relationship with patients and help them better cope with unhealthy emotions. (2) Health education was provided through self-developed booklets and question-and-answer sessions to publicize the fundamental knowledge and make sure all patients have a full understanding of the disease and related treatments. (3) Dietary guidelines were set out to encourage a light, healthy diet with fruits and vegetables, free of irritating food, and containing a limited amount of oily food. (4) Behavioral guidelines were developed to address the importance of quitting tobacco use and prevent eye strain due to excessive eye use with tailored eye care plans.
Study NCT04421339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
Study NCT04421339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
Study NCT05513183 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative blood and peritoneal fluid samplings during HIPEC
Description: - Intraoperative samplings of blood and peritoneal fluids during HIPEC :~* Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~* Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)
Study NCT04188756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
Study NCT05442346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γ-globin reactivated autologous hematopoietic stem cells
Description: gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
Study NCT06420050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instagram Intervention
Description: The intervention consists of a study Instagram page, which will post intervention content every day for 42 days.
Study NCT05175950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose
Study NCT05175950 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT06468163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug infusion into joint through catheter.
Description: With or without using catheter after DAIR operation for drug infusion.
Study NCT06468163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug infusion into joint through catheter.
Description: With or without using catheter after DAIR operation for drug infusion.
Study NCT05820113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep learning based reconstruction of T2-TSE sequence
Description: A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
Study NCT06249828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MegaCarti^®
Description: MegaCarti® application after microfracture through athroscopic or incision surgery
Study NCT06249828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery
Study NCT06249828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery
Study NCT05521113 — intervention group
Intervention type: BEHAVIORAL
Intervention: Home Rehabilitation Monitoring System
Description: The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
Study NCT05521113 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health coaching calls
Description: 12 telephone-based health coaching calls over a 12-week period
Study NCT04748536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL201104
Description: lyophilised powder for reconstitution for IV dosing
Study NCT04748536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for IRL201104
Study NCT04796675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Study NCT05674409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family-Involved Treatment (B-FIT)
Description: Brief Family-Involved Treatment (B-FIT) is a manualized, 3-session intervention for Alcohol Use Disorder (AUD). Designed to be implemented in combination with any existing alcohol treatment program, the goals of B-FIT are to (1) increase reinforcement for AUD treatment engagement, (2) increase positive rewards from drinking reductions, and (3) decrease drinking cues by decreasing negative communication and increasing positive communication.
Study NCT05674409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)
Description: Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
Study NCT05674409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)
Description: Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
Study NCT05415514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Instrumented assessment of muscle function
Description: During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
Study NCT05805020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cellvizio
Description: During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
Study NCT03585946 — intervention group
Intervention type: DRUG
Intervention: Site specific standard of care comparison
Description: Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
Study NCT06242938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early intensive antihypertensive treatment
Description: 1. Treatment starts within 1 hour after randomization~2. SBP target:130-140 mmHg within 1 hour after treatment~3. The researchers can independently select oral + intravenous antihypertensive medications. Any type of antihypertensive drugs can be selected (eg. β-blokers, α-blockers, CCBs, ARBs/ACEIs, diuretic, etc.).
Study NCT03825536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Methamphetamine
Description: In this phase IV double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For the oral methamphetamine treatment arm, an initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.
Study NCT05409755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivacy
Description: Vivacy and minoxidil
Study NCT03825536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: In this phase IV double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For placebo treatment phase, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
Study NCT05923645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (Hf rTMS)
Description: TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient
Study NCT05702541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses
Study NCT05702541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses
Study NCT05702541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based cleaning and disinfection system
Description: Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
Study NCT05668299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrachFlush
Description: See detailed description previously entered.
Study NCT04816864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: extracardiac vagal nerve stimulation (ECANS) + EPS
Description: The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~1. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~2. ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~3. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.
Study NCT04859309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActiveHip+ mobile application
Description: The mobile application with the educational and multidisciplinary tele-rehabilitation program.
Study NCT04859309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care in a hip fracture
Description: The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
Study NCT05773625 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Just-In-Time Adaptive Intervention
Description: Participants will be exposed to a new innovative app to test.
Study NCT04826835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Description: Participants will:~* Receive four supervised exercise classes (twice per week for two weeks) one-to-one by an exercise specialist;~* Practice six sessions of home-based exercise (three times per week for two weeks);~* Practice unsupervised respiratory muscle training at home (twice daily for two weeks);~* Receive usual care.
Study NCT04826835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control
Description: Participants will:~* Receive four recorded health education talks (twice per week for two weeks)~* Receive a brief health education booklet on dietary education for chronic lung conditions, preoperative preparation, and postoperative recovery~* Receive usual care.
Study NCT06549881 — intervention group
Intervention type: PROCEDURE
Intervention: emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
Description: emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
Study NCT05177692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vguard
Description: VGuard is a system that has been created to ensure that the patients´ ventricular drainage system and pressure monitor closely follows the patient when the head is adjusted vertically. The system consists of a pressure sensor that is connected to the patients´ head. The pressure sensor is connected to a motorized column that automatically adjusts to keep the zero level at level with the patients´ head at all times.
Study NCT05373030 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant adenovirus type-5-vectored COVID-19 vaccine
Description: One dose COVID-19 vaccine
Study NCT05373030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus type-5-vectored COVID-19 vaccine
Description: One dose COVID-19 vaccine
Study NCT05545085 — intervention group
Intervention type: DEVICE
Intervention: Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device
Description: Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
Study NCT05682274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial restoration approach combined with CAF+CTG
Description: The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.
Study NCT06154720 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
Study NCT06327360 — intervention group
Intervention type: OTHER
Intervention: Psychological questionnaires
Description: The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.
Study NCT05933694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-powered Spirometry Interpretation Report
Description: A report generated by artificial intelligence powered software that assessed technical quality of spirometry and estimates the diagnostic probability of six categories: COPD/Asthma/ILD/ Normal/Other obstructive/Other Unidentified
Study NCT06532058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD107 capsule，Venclexta and Azacitidine
Description: QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）
Study NCT05068479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral Laser Scleral Microporation procedure
Description: Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
Study NCT05434585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABO1009-DP
Description: Vaccine
Study NCT05434585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABO-CoV.617.2
Description: Vaccine
Study NCT05434585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05495698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: single-inhaler triple therapy (Trimbow)
Description: Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
Study NCT05495698 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: E-health application: Curavista app & FindAir e-device
Description: Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
Study NCT05495698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: multi-inhaler triple therapy (Qvar + Bevespi)
Description: Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
Study NCT06546059 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: narrow band ultraviolet-B
Description: vitiligo patients will recevie twice sessions per week
Study NCT05115708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ab externo viscotrabeculotomy
Description: In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group
Study NCT05115708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
Description: The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
Study NCT05739539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: optical coherence tomography angiography
Description: optical coherence tomography angiography will be done postoperatively in both groups to assess the retinal microvascular changes
Study NCT04710368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab Injections
Description: Administered on day 1 (the day of the first treatment) and through week 26 with a personal injector or prefilled auto injector/pens.